



December 09, 2019

The Secretary Listing Department, BSE Limited, 1 st Floor, Phiroze Jeejeebhoy Towers Dalal Street, Mumbai 400001 Scrip Code: 540975	The Manager, Listing Department, The National Stock Exchange of India Ltd Exchange Plaza, C-1, Block G Bandra Kurla Complex Bandra (East), Mumbai 400051 Scrip Symbol: ASTERDM
---	--

Dear Sir/ Madam,

Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 pursuant to acquisition of a step-down subsidiary, Premium Healthcare Limited, UAE.

In furtherance to the announcement made by the Company on October 31, 2019 on the Captioned subject the Company through its Subsidiary, Aster DM Healthcare FZC, Completed acquisition of 80% stake in Premium Healthcare Limited, UAE on December 5, 2019 and confirmation received by the Company from Dubai International Financial Centre Authority (DIFCA) on December 08, 2019.

In this regard, as per Circular Number CIR/CFD/CMD/4/2015 dated September 09, 2015 pertaining to continuous disclosure requirements for Listed Entities under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed Annexure I for your records.

We request you to kindly take the above information on record.

Thank You.

For Aster DM Healthcare Limited


Puja Aggarwal
Company Secretary and Compliance Officer



Aster DM Healthcare Limited
CIN-L8510KL2008PLC021703
IX/475L, Aster Medcity, Kuttisahib Road
Near Kothad Bridge, South Chittoor PO
Cheranalloor, Kochi- 682027, Kerala, India
Tel: +91 484 6699999, Fax: +91 484 6699862
Email: cs@asterdmhealthcare.com
Website: www.asterdmhealthcare.com

Annexure I

Sl No	Particulars	
1	Name of the target entity, details in brief such as size, turnover etc.;	Premium Healthcare Limited, UAE ("THE CLINIC") Paid up Capital as on date: AED 183,000 Turnover for 2018: AED 9,775,601 Net worth as on 31-12-2018: AED 1,878,460
2	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arms length";	No
3	Industry to which the entity being acquired belongs;	Healthcare
4	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	It is a bolt-on acquisition which fits with our existing medcare brand of clinics
5	Brief details of any governmental or regulatory approvals required for the acquisition;	Approval from Dubai International Financial Centre Authority (DIFCA) and Dubai Health Authority (DHA) has been received
6	Indicative time period for completion of the acquisition	Acquisition of shares completed on December 05, 2019 and confirmation received by the Company on December 08, 2019
7	Nature of consideration - whether cash consideration or share swap and details of the same	Cash
8	Cost of acquisition or the price at which the shares are acquired;	AED 8.69 Million
9	Percentage of shareholding / control acquired and / or number of shares acquired;	80% of shareholding acquired on completion of the transaction
10	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	The target company is medical clinic operating in UAE. The Company was incorporated on 22 June 2009. The turnover of the Company for the immediately preceding three calendar years are as follows: 2016: AED 9,951,810 2017: AED 9,228,778 2018: AED 9,775,601

